Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial

References

• Thom T., Haase N., Rosamond W., Howard V. J., Rumsfeld J., Manolio T., et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85–151
   PubMed Web of Science ®Google Scholar
• Cuffe M. S., Califf R. M., Adams K. F., Jr., Benza R., Bourge R., Colucci W. S., et al. Short‐term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541–7
   PubMed Web of Science ®Google Scholar
• Fonarow G. C., Abraham W. T., Albert N. M., Gattis W. A., Gheorghiade M., Greenberg B., et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE‐HF): rationale and design. Am Heart J 2004; 148: 43–51
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Zannad F., Sopko G., Klein L., Pina I. L., Konstam M. A., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958–68
   PubMed Web of Science ®Google Scholar
• Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute Heart CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531–40
   PubMed Web of Science ®Google Scholar
• Mebazaa A. The SURVIVE Trial: Comparison of Dobutamine and Levosimendan on Survival in Acute Decompensated Heart Failure [abstract]., American Heart Association Scientific Sessions 2005; Presented 16 November 2005
   Google Scholar
• Packer M. REVIVE II: Multicenter Placebo‐Controlled Trial of Levosimendan on Clinical Status in Acutely Decompensated Heart Failure [abstract]., American Heart Association Scientific Sessions 2005; Presented 14 November 2005
   Google Scholar
• Felker G. M., Leimberger J. D., Califf R. M., Cuffe M. S., Massie B. M., Adams K. F., Jr., et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004; 10: 460–6
   PubMed Web of Science ®Google Scholar
• Klein L., O'Connor C. M., Leimberger J. D., Gattis‐Stough W., Pina I. L., Felker G. M., et al. Lower serum sodium is associated with increased short‐term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME‐CHF) study. Circulation 2005; 111: 2454–60
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Stough W. G., O'Connor C. M., Abraham W. T., Greenberg B., Young J. B., et al. Serum Sodium Concentration and Mortality in Patients Admitted with Heart Failure: An Analysis of OPTIMIZE‐HF [abstract]. J Card Fail 2005; S183
   Google Scholar
• Gheorghiade M., Hellkamp A., Pina I. L., Fonarow G. C., De Marco T., Pauly D., et al. Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial [abstract]. J Am Coll Cardiol 2005; 45: 145A
   Web of Science ®Google Scholar
• Gheorghiade M., Gattis W. A., O'Connor C. M., Adams K. F., Jr., Elkayam U., Barbagelata A., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963–71
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Gattis W. A., Barbagelata A., Adams K. F., Jr., Elkayam U., Orlandi C., et al. Rationale and study design for a multicenter, randomized, double‐blind, placebo‐controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003; 145: S51–S54
   PubMed Web of Science ®Google Scholar
• Oren R. M. Hyponatremia in congestive heart failure. Am J Cardiol 2005; 95: 2B–7B
   PubMed Web of Science ®Google Scholar
• Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10–24
   PubMed Web of Science ®Google Scholar
• Sonnenblick M., Friedlander Y., Rosin A. J. Diuretic‐induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993; 103: 601–6
   PubMed Web of Science ®Google Scholar
• Francis G. S., Goldsmith S. R., Levine T. B., Olivari M. T., Cohn J. N. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370–7
   PubMed Web of Science ®Google Scholar
• Francis G. S., Benedict C., Johnstone D. E., Kirlin P. C., Nicklas J., Liang C. S., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–9
   PubMed Web of Science ®Google Scholar
• Butler J., Forman D. E., Abraham W. T., Gottlieb S. S., Loh E., Massie B. M., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331–8
   PubMed Web of Science ®Google Scholar
• Costanzo M. R., Heywood J., DeMarco T., Fonarow G. C., Wynne J. Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure [abstract]. J Am Coll Cardiol 2004; 43: 180A
   Web of Science ®Google Scholar
• Domanski M., Norman J., Pitt B. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705–8
   PubMed Web of Science ®Google Scholar
• Hasselblad V., Stough W. G., Shah M. R., Lokhnygina J. C., Burnett J. C., Gheorghiade M., et al. Relation between diuretic dose and outcome in a heart failure population: results of the ESCAPE trial [abstract]. J Card Fail 2005; 11: S157
   Web of Science ®Google Scholar
• Eshaghian S., Horwich T. B., Fonarow G. C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006; 97: 1759–64
   PubMed Web of Science ®Google Scholar
• Emerman C. L., De Marco T., Costanzo M. R., Peacock W. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry [abstract]. J Card Fail 2004; 10: S116
   Web of Science ®Google Scholar
• Levy W. C., Mozaffarian D., Linker D. T., Sutradhar S. C., Anker S. D., Cropp A. B., et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006; 113: 1424–33
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Niazi I., Ouyang J., Czerwiec F., Kambayashi J., Zampino M., et al. Vasopressin V2‐receptor blockade with tolvaptan in patients with chronic heart failure: results from a double‐blind, randomized trial. Circulation 2003; 107: 2690–6
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Gottlieb S. S., Udelson J. E., Konstam M. A., Czerwiec F., Ouyang J., et al. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006; 97: 1064–7
   PubMed Web of Science ®Google Scholar
• Gheorghiade M., Orlandi C., Burnett J. C., DeMets D., Grinfeld L., Maggioni A., et al. Rationale and design of the multicenter, randomized, double‐blind, placebo‐controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005; 11: 260–9
   PubMed Web of Science ®Google Scholar